Pharmaceuticals & Biotechnology Editor | 03/10/2010
An Interview with Nachum Kaplan, Vice President of Microbiology at Affinium Pharmaceuticals on bacterial fatty-acid synthesis as a target for AFN-1252: a novel and selective-spectrum antibiotic for the treatment of Staphylococcal infection.
Download PDF Attachment
Upcoming Events
DigIT Pharma AI Commercial Excellence & Health 2025
September 1 - 3, 2025
Palace Hotel Berlin, Germany
Register Now |
View Agenda |
Learn More
GenAI Life Science & Health 2025
September 1 - 3, 2025
Berlin, Germany
Register Now |
View Agenda |
Learn More